Latest Press Releases

Derm-biome Pharmaceuticals' Topical Therapy Shows Positive Results in Preclinical Skin Cancer Trial: Drug Prevents the Development of Precancerous Skin Conditions and Treats Existing Skin Cancers With No Observable Side Effects

VANCOUVER, British Columbia, April 17, 2024 (GLOBE NEWSWIRE) -- The rates of precancerous skin conditions and skin cancers are soaring in many parts of the world. Actinic keratosis (AK) is the most common form of precancer, with over 40 ...

London Research & Pharmaceuticals presents the Advancement of LRP-661, their Oral Cannabidiol Sulphate Drug Candidate at the Prestigious Epilepsy Therapies & Diagnostics Development (ETDD) XVII Conference in Miami

LONDON, Ontario, April 15, 2024 (GLOBE NEWSWIRE) -- London Research & Pharmaceuticals has recently publicized data about its lead compound LRP-661 or Cannabidiol sulphate (CBDS), highlighting its safety, efficacy, bioavailability, and ...

Medical Students Partner with Barber Shops to Tackle A Silent Killer

Texas Tech University Health Sciences Center medical students have worked with barber shops and beauty salons to tackle high blood pressure. The Barber Shop Blood Pressure Group allows customers to do one-stop shopping when it comes to their barber ...

Vascepa® (icosapent ethyl) 26% Reduction in Key Secondary Composite Endpoint of Cardiovascular Death, Heart Attacks and Stroke Demonstrated in REDUCE-IT™ Supports 25% Overall Reduction in Five-Point Major Adverse Cardiovascular Event Primary Composite Endpoint

Landmark Cardiovascular Risk Reduction Benefits Demonstrated in REDUCE-IT Are Largest of Any Major Cardiovascular Outcomes Study of a Drug Intended to Address Residual Cardiovascular Risk Remaining After Cholesterol Management CHICAGO , Nov. ...

Forxiga significantly reduced hospitalisation for heart failure or CV death in a broad patient population with type-2 diabetes in the landmark DECLARE-TIMI 58 trial

Fewer MACE events observed with Forxiga vs. placebo,but this finding did not reach statistical significance No imbalance in amputations, fractures, bladder canceror Fournier's gangrene with Forxiga vs. placebo MISSISSAUGA, ON , Nov. ...

Press Releases

Premium Press Releases »

Derm-biome Pharmaceuticals' Topical Therapy Shows Positive Results in Preclinical Skin Cancer Trial: Drug Prevents the Development of Precancerous Skin Conditions and Treats Existing Skin Cancers With No Observable Side Effects

London Research & Pharmaceuticals presents the Advancement of LRP-661, their Oral Cannabidiol Sulphate Drug Candidate at the Prestigious Epilepsy Therapies & Diagnostics Development (ETDD) XVII Conference in Miami

Press Releases »

Medical Students Partner with Barber Shops to Tackle A Silent Killer

Vascepa® (icosapent ethyl) 26% Reduction in Key Secondary Composite Endpoint of Cardiovascular Death, Heart Attacks and Stroke Demonstrated in REDUCE-IT™ Supports 25% Overall Reduction in Five-Point Major Adverse Cardiovascular Event Primary Composite Endpoint

Forxiga significantly reduced hospitalisation for heart failure or CV death in a broad patient population with type-2 diabetes in the landmark DECLARE-TIMI 58 trial

Medindia Newsletters